CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thr ...
The federal government will unveil the next round of major projects that will get fast-tracked approvals later this week, ...
CorMedix again raises its full-year 2025 pro forma net revenue guidance to a range of $390 to $410 million, and fourth quarter net revenue guidance to a range of $115 to $135 million. In addition, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback